TRU-SENTIMENT · DeltaNeutral
MLTX Trading Analysis - 11/18/2026 11:34 AM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
MLTX (MoonLake Immunotherapeutics Class A Ordinary Share) at $10.93. True Sentiment Bullish, delta 40-60 call 100% / put 0%, call $17,385 vs put $0. RSI 42.4.
- Symbol
- MLTX
- Price
- $10.93
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-18 11:34:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)From the TRUE SENTIMENT OPTIONS JSON (delta 40-60 only):
Call Volume: $17,385 (100.00%) Put Volume: $0 (0.00%) Total: $17,385
Sentiment is Bullish with 169 call contracts vs 0 put contracts, 3 call trades vs 0 put trades. Pure directional conviction is call-sided, but only 3 contracts analyzed (filter ratio 0.9% of 346 total). This suggests bullish near-term expectation from a tiny directional sample, diverging from the bearish technical alignment (price below all SMAs, RSI < 50).
Key Statistics: MLTX
Fundamental Snapshot
Valuation
| EPS (trailing 12 mo) | $-3.66 |
| Market cap | $931.07M |
| Shares outstanding | 85.1M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| Beta | 0.06 |
| 52-week low | $9.46 |
| 52-week high | $23.29 |
| Historical volatility | 80.3% |
Ownership & trading
| Institutional ownership | 10.5% |
| Average daily volume | 1.7M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
Recent general-knowledge context for MLTX (MoonLake Immunotherapeutics, a clinical-stage biotech focused on inflammatory diseases):
- Pipeline updates from sonelokimab (nanobody IL-17 inhibitor) in hidradenitis suppurativa and psoriatic arthritis remain the primary catalyst drivers for the stock.
- Earlier in 2026, positive topline data readouts lifted MLTX from sub-$10 to the $13+ range seen in the daily history (e.g., 2026-11-11 close at $13.50).
- No confirmed near-term earnings date is reflected in the embedded data; fiscal year end is listed as 2025-12-01 with no ex-dividend or dividend data.
- Biotech sector sentiment has been mixed on small-cap names with negative EPS, which aligns with MLTX's negative trailing EPS of -3.66 and low institutional ownership of 10.51%.
- Headlines around trial progress likely contributed to the late-October and early-November rallies, but the embedded price action shows a pullback into mid-November.
This news context is separated from the strict data analysis below, which is based only on the provided embedded datasets.
Fundamental Analysis
Based strictly on the FUNDAMENTALS JSON:
- Trailing EPS is -3.66; the company is not profitable (no positive earnings trend in the data).
- Trailing PE, forward PE, PEG ratio, price-to-book, profit margins, ROE, debt-to-equity, and free cash flow are all null or not provided.
- Revenue growth, total revenue, and analyst target mean price are null; no analyst consensus or recommendation key is available.
- Market cap is $931,070,580 with shares outstanding of 85,107,000 and a dividend yield of 0.00%.
- 52-week high is $23.29 and 52-week low is $9.46; current price (~$11.13) sits in the lower half of the annual range.
- Institutional ownership is only 10.51%, indicating limited institutional support.
- Beta is 0.06 (very low market correlation); historical volatility is 80.32% (high idiosyncratic vol).
- Fundamentals show a loss-making small-cap with no valuation anchors; this diverges from the bullish options sentiment and the October–November price spike.
Current Market Position
From the embedded data: current price is $11.13 (indicators JSON, 2026-11-17 close). Minute bars show 2026-11-17 open at $11.72 and a decline to $11.13 by daily close; intraday on 2026-11-18 last printed $10.93 at 11:05. Recent daily action dropped from $13.50 (2026-11-11) to $11.70 (2026-11-16) to $11.13 (2026-11-17).
Minute-bar momentum: first 5 bars on 2026-11-17 slid from $11.65 to $11.45; last 5 bars on 2026-11-18 hovered $10.85–$10.97 then $10.93, showing weak/flat intraday tone.
Technical Analysis
Technical Indicators
Price ($11.13) is below SMA 5 ($12.40), SMA 20 ($11.98), and SMA 50 ($11.76) — bearish alignment with no golden cross. RSI at 42.42 shows weak momentum, not oversold. MACD (0.09) above signal (0.08) with positive histogram (0.02) is marginally bullish but weak. Bollinger Bands: price near lower band ($10.54) after mid-range expansion. 30-day range high $13.90, low $9.48; price is ~18% above the 30d low and ~20% below the 30d high.
True Sentiment Analysis (Delta 40-60 Options)
From the TRUE SENTIMENT OPTIONS JSON (delta 40-60 only):
Call Volume: $17,385 (100.00%) Put Volume: $0 (0.00%) Total: $17,385
Sentiment is Bullish with 169 call contracts vs 0 put contracts, 3 call trades vs 0 put trades. Pure directional conviction is call-sided, but only 3 contracts analyzed (filter ratio 0.9% of 346 total). This suggests bullish near-term expectation from a tiny directional sample, diverging from the bearish technical alignment (price below all SMAs, RSI < 50).
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.